-
公开(公告)号:US20250122509A1
公开(公告)日:2025-04-17
申请号:US19002832
申请日:2024-12-27
Applicant: TOOLGEN INCORPORATED
Inventor: Jin-Soo Kim , Seung Woo Cho , Sojung Kim
IPC: C12N15/52 , C12N9/16 , C12N9/22 , C12N15/10 , C12N15/11 , C12N15/63 , C12N15/82 , C12N15/85 , C12N15/90
Abstract: The present disclosure relates to targeted genome editing in eukaryotic cells or organisms. More particularly, the present disclosure provides for compositions and methods that may induce modifications in target endogenous nucleic acid sequences in nucleuses of eukaryotic cells. For example, disclosed herein are methods of modifying a target endogenous nucleic acid sequence in a nucleus of a eukaryotic cell in vitro or ex vivo, comprising: preparing a composition comprising a recombinant Cas9 protein, a single guide RNA, and a Cas9/RNA complex formed by at least a part of said recombinant Cas9 protein and single guide RNA, and introducing a Cas9/RNA complex into the eukaryotic cell in vitro or ex vivo, wherein in the composition, the single guide RNA is at least two-fold molar excess over the recombinant Cas9 protein, wherein the Cas9/RNA complex is a combination of the recombinant Cas9 protein and the single guide RNA, and wherein the Cas9/RNA complex is complexed prior to being introduced into the eukaryotic cell; wherein the single guide RNA is in vitro transcribed RNA or synthetic RNA, wherein the combination of the recombinant Cas9 protein and the single guide RNA produces a modification of the target endogenous nucleic acid sequence in the nucleus of the eukaryotic cell.
-
公开(公告)号:US12275963B2
公开(公告)日:2025-04-15
申请号:US16611383
申请日:2018-05-08
Applicant: TOOLGEN INCORPORATED
Inventor: Seok Joong Kim , Yoon-Young Kim , Ho-Sung Yu , In-Young Jung , Jung Min Lee
IPC: A61K39/00 , C07K14/705 , C07K16/28 , C12N5/078 , C12N5/0783 , C12N9/22 , C12N15/10 , C12N15/113 , C12N15/115 , C12N15/117 , C12N15/87 , C07K14/725
Abstract: The presents invention relates to a composition for manipulating an immune cell which is used for artificially manipulating an immune cell. More particularly, the present invention relates to a composition for manipulating an immune cell which is used for artificially manipulating an immune cell and a manipulated immune cell comprising an artificially modified immunity regulating gene and an artificial receptor which is produced using the composition, and use thereof.
-
公开(公告)号:US20240166999A1
公开(公告)日:2024-05-23
申请号:US18424920
申请日:2024-01-29
Applicant: TOOLGEN INCORPORATED
Inventor: Eun Ji SHIN , Kang In LEE , Yu Ri CHOI , Hye Jung SHIN , Jae Young LEE , Hwan Yeul YU
IPC: C12N5/0775 , C12N9/16 , C12N15/11 , C12N15/86
CPC classification number: C12N5/0665 , C12N9/16 , C12N15/11 , C12N15/86 , C12N2310/20 , C12N2510/00 , C12Y301/00
Abstract: Mesenchymal stem cells, a preparation method therefor, and a cell therapeutic agent using same have hemocompatibility since thrombosis thereof is suppressed after the expression or activation level of blood coagulation initiating factor CD142 is reduced or inhibited. When intravascularly administered, the mesenchymal stem cells have improved hemocompatibility since thrombosis thereof, which can be caused by the administered mesenchymal stem cells, is suppressed.
-
14.
公开(公告)号:US20240139254A1
公开(公告)日:2024-05-02
申请号:US18407597
申请日:2024-01-09
Applicant: TOOLGEN INCORPORATED
Inventor: Eun Ji SHIN , Kang In LEE , Yu Ri CHOI , Hye Jung SHIN , Jae Young LEE
IPC: A61K35/28 , C12N5/0775 , C12N9/22 , C12N15/113
CPC classification number: A61K35/28 , C12N5/0662 , C12N9/22 , C12N15/113 , C12N2310/20
Abstract: Provided are mesenchymal stem cells, a preparation method therefor, and a use thereof, the mesenchymal stem cell having oxidative stress resistance by reducing or inhibiting the expression or activity level of KEAP1, which is a negative regulator of Nrf2, so as to increase the activity of Nrf2.
-
公开(公告)号:US11920151B2
公开(公告)日:2024-03-05
申请号:US16332036
申请日:2017-09-13
Applicant: TOOLGEN INCORPORATED , Seoul National University R&DB Foundation , INSTITUTE FOR BASIC SCIENCE
Inventor: Daesik Kim
IPC: C12N15/90 , C12N9/22 , C12N9/78 , C12N15/113 , C12Q1/6806 , C12Q1/6869 , G16B30/00
CPC classification number: C12N15/90 , C12N9/22 , C12N9/78 , C12N15/113 , C12Q1/6806 , C12Q1/6869 , G16B30/00 , C12Y305/04004
Abstract: Provided are: a composition for DNA double-strand breaks (DSBs), comprising (1) a cytosine deaminase and an inactivated target-specific endonuclease, (2) a guide RNA, and (3) a uracil-specific excision reagent (USER); a method for producing DNA double-strand breaks by means of a cytosine deaminase using the composition; a method for analyzing a DNA nucleic acid sequence to which base editing has been introduced by means of a cytosine deaminase; and a method for identifying (or measuring or detecting) base editing, base editing efficiency at an on-target site, an off-target site, and/or target specificity by means of a cytosine deaminase.
-
公开(公告)号:US20230374524A1
公开(公告)日:2023-11-23
申请号:US18313946
申请日:2023-05-08
Applicant: TOOLGEN INCORPORATED
Inventor: Jin-Soo Kim , Seung Woo Cho , Sojung Kim
IPC: C12N15/52 , C12N15/82 , C12N15/63 , C12N9/16 , C12N15/11 , C12N15/10 , C12N15/90 , C12N15/85 , C12N9/22
CPC classification number: C12N15/52 , C12N15/8216 , C12N15/63 , C12N9/16 , C12N15/111 , C12N15/102 , C12N15/907 , C12N15/85 , C12N9/22 , C12Y301/21 , C12N2310/10 , C12N2310/20 , C12N2310/531
Abstract: The present invention relates to targeted genome editing in eukaryotic cells or organisms. More particularly, the present invention relates to a composition for cleaving a target DNA in eukaryotic cells or organisms comprising a guide RNA specific for the target DNA and Cas protein-encoding nucleic acid or Cas protein, and use thereof.
-
公开(公告)号:US20230053781A1
公开(公告)日:2023-02-23
申请号:US17792771
申请日:2021-01-14
Inventor: Eun Ji SHIN , Kang In LEE , Nahee LEE , Jong Wook CHANG , Na Kyung LEE , Duk Lyul NA , Jae Young LEE
Abstract: The present disclosure provides a pharmaceutical composition for treating Alzheimer's disease and use thereof, the pharmaceutical composition containing, as an active ingredient, stem cells (SC) having high adaptability under hypoxic conditions. Particularly, the present disclosure discloses a pharmaceutical composition for alleviating or treating the symptoms of Alzheimer's disease, the pharmaceutical composition containing, as an active ingredient, mesenchymal stem cells (MSC) which have high adaptability or viability in hypoxic environments and comprise one or more knock-out HIF1AN genes.
-
公开(公告)号:US20210147798A1
公开(公告)日:2021-05-20
申请号:US16611383
申请日:2018-05-08
Applicant: TOOLGEN INCORPORATED
Inventor: Seok Joong KIM , Yoon-Young KIM , Ho-Sung YU , In-Young JUNG , Jung Min LEE
IPC: C12N5/078 , C12N9/22 , C12N15/113 , C12N15/115 , C12N15/10 , C07K14/705 , C12N15/87
Abstract: The presents invention relates to a composition for manipulating an immune cell which is used for artificially manipulating an immune cell. More particularly, the present invention relates to a composition for manipulating an immune cell which is used for artificially manipulating an immune cell and a manipulated immune cell comprising an artificially modified immunity regulating gene and an artificial receptor which is produced using the composition, and use thereof.
-
公开(公告)号:US20200277630A1
公开(公告)日:2020-09-03
申请号:US16650993
申请日:2018-09-28
Applicant: TOOLGEN INCORPORATED , SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION , SEOUL NATIONAL UNIVERSITY HOSPITAL
Inventor: Dong Woo SONG , Jung Min LEE , Un Gi KIM , Jeong Hun KIM , Dong Hyun JO
IPC: C12N15/86 , C12N15/113 , C12N9/22 , A61P27/02
Abstract: The present invention relates to a composition for gene manipulation for treating or improving a retinal dysfunction disease or a method using the same. More particularly, the present invention relates to a composition for gene manipulation including a guide nucleic acid capable of targeting a retinal function-forming gene and a method of treating or improving a disease caused by retinal dysfunction by artificially manipulating and/or correcting a retinal function-forming gene using the same.
-
公开(公告)号:US20200149022A1
公开(公告)日:2020-05-14
申请号:US16628199
申请日:2018-07-06
Applicant: TOOLGEN INCORPORATED
Inventor: Young-Hoon KIM , Min Hee JUNG , Joonsun LEE , Eunji SHIN , Kang In LEE , Seokjoong KIM , Jeongjoon LEE
Abstract: The present invention relates to an artificially engineered CRISPR/Cas9 system. More particularly, the present invention relates to an artificially engineered CRISPR enzyme having enhanced target specificity and a use of an artificially engineered CRISPR/Cas9 system including the same enzyme in genome and/or epigenome manipulation or modification, genome targeting, genome editing, and in vitro diagnosis, etc.
-
-
-
-
-
-
-
-
-